|
Synonyms: TAK 165 | TAK-165 | TAK165
Comment: Mubritinib is a reversible inhibitor of EGFR and HER2. This compound is a Phase I clinical candidate.
|
|
2D Structure
|
|
Physico-chemical Properties
|
|
|
Hydrogen bond acceptors
|
3
|
|
Hydrogen bond donors
|
0
|
|
Rotatable bonds
|
11
|
|
Topological polar surface area
|
65.97
|
|
Molecular weight
|
468.18
|
|
XLogP
|
5.37
|
|
No. Lipinski's rules broken
|
2
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
SMILES / InChI / InChIKey
|
|
|
Canonical SMILES
|
FC(c1ccc(cc1)C=Cc1occ(n1)COc1ccc(cc1)CCCCn1nncc1)(F)F
|
|
Isomeric SMILES
|
FC(c1ccc(cc1)/C=C/c1occ(n1)COc1ccc(cc1)CCCCn1nncc1)(F)F
|
|
InChI
|
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
|
|
InChI Key
|
ZTFBIUXIQYRUNT-MDWZMJQESA-N
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
|